Sponsor

Prof. Wolfgang Janni

Clinical research sponsor

Published trials6
Recruiting shown3
Roles1
SourceClinicalTrials.gov

Clinical trials

6 shown
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseNCT06643585 · lead sponsor · 2025-04-22
RECRUITING
Standard Surveillance vs. Intensive Surveillance in Early Breast CancerNCT05658172 · lead sponsor · 2022-12-07
RECRUITING
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementNCT05362760 · lead sponsor · 2022-04-27
RECRUITING
Detect V / CHEVENDO (Chemo vs. Endo)NCT02344472 · lead sponsor · 2015-09-01
UNKNOWN
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).NCT02035813 · lead sponsor · 2014-01-01
COMPLETED
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCsNCT01619111 · lead sponsor · 2012-02-01
COMPLETED

Sponsor roles

lead sponsor6

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.